Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

High-Resolution Mass Spectrometry for Biologic Characterization

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

High-Resolution Mass Spectrometry for Biologic Characterization

CELL & GENE | RNA | BIOLOGICS

A stylized 3D rendering of a DNA double helix, composed of light-colored spheres on a translucent blue backbone, set against a soft-focus, light blue background.

Proven Intelligence in Analytical Characterization.

Executive Summary

High-resolution mass spectrometry provides definitive characterization of complex biologics, including AAV vectors, RNA/LNP systems, and cell-based constructs. This analytical approach moves beyond basic identity and purity assays to deliver precise data on protein sequences, post-translational modifications (PTMs), and defined quality attributes (CQAs). Integrating these methods early in development generates a robust data package that supports successful IND submissions and alignment with global regulatory expectations, including ICH guidelines.

A close-up of a scientist in blue gloves gently holding a small, white laboratory mouse, likely in a research setting.

Frequently Asked Questions

How does mass spectrometry de-risk the CMC package for AAV vectors ahead of an IND submission?

Mass spectrometry provides unambiguous confirmation of capsid protein identity (VP1, VP2, VP3) and their stoichiometric ratios. It also identifies and quantifies post-translational modifications and process-related impurities, such as host cell proteins (HCPs). This high-resolution data is foundational for demonstrating product consistency and safety, directly supporting IND-enabling toxicology studies.

What is the role of mass spectrometry in characterizing LNP therapy and RNA payloads?

For lipid nanoparticle (LNP) systems, mass spectrometry is used to verify the identity and purity of ionizable lipids, helper lipids, and PEG-lipids. For RNA payloads, it can confirm sequence integrity and identify modifications. This level of detail is necessary for understanding the stability and delivery efficacy of RNA therapeutics.

Can these advanced analytical methods be performed under GxP conditions for regulatory filings?

Yes. Our analytical laboratories, part of a >100,000 sq ft facility, operate in a phase-appropriate manner. Assays can be developed and qualified for research purposes and subsequently validated for use in GxP-compliant environments to support CMC sections of IND, IMPD, and other global regulatory submissions.

A promotional graphic for Franklin BioLabs showcasing a list of their notable scientific publications in preclinical and translational research.

Defining Product Attributes with Analytical Precision

The structural complexity of next-generation therapeutics demands analytical methods that can resolve subtle but significant variations in product quality. While standard assays confirm titer and general purity, high-resolution mass spectrometry provides a deeper level of molecular characterization. It is a direct method for verifying primary amino acid sequences, identifying protein modifications, and profiling impurities that can impact efficacy and immunogenicity.

This analytical rigor is not an isolated exercise. It is an integrated component of a successful development program. The principle of analytical fidelity extends upstream to the very isolation of genetic material. The use of high-fidelity polymerases to ensure accurate amplification of viral genomes from source tissues is a precursor to meaningful downstream analysis (PMID: 34448594). Without a precise starting point, subsequent characterization lacks a reliable foundation.

Applications Across Next-Generation Therapeutic Platforms

A tailored analytical strategy is required for each distinct modality. Mass spectrometry offers the flexibility to address the unique challenges presented by different biologic platforms.

  • AAV Vectors: Confirms the precise stoichiometric ratio of capsid proteins (VP1/VP2/VP3), a CQA linked to vector infectivity and function. It also maps PTMs like phosphorylation or deamidation that can arise during manufacturing.

  • RNA Payloads & LNP Delivery: For non-viral systems, mass spectrometry is applied to characterize the lipid components of LNPs. It provides structural confirmation and purity analysis of the ionizable and helper lipids that are fundamental to payload protection and delivery.

  • Cell-Based Modalities: In CAR-T and TCR-T therapies, mass spectrometry can be used to characterize the engineered receptor proteins, confirming expression and identifying modifications that could affect target binding.

A marketing fact sheet from Franklin Biolabs about the scientific benefits of Mauritian cynomolgus macaques for preclinical research, featuring a photo of the primates.

Building a Data-Driven Path to IND

A robust analytical data package is the bedrock of a successful regulatory submission. By employing high-resolution mass spectrometry, therapeutic developers can demonstrate a comprehensive understanding of their product to regulatory bodies like the FDA and MHRA. This detailed characterization supports process development, establishes release criteria, and provides the molecular-level evidence needed to accelerate programs toward the clinic. This approach is central to achieving an 18-24 month IND timeline.

The track record of our founding scientific leadership includes a 100% successful IND rate since 2019, a history built on this type of analytical depth. Franklin Biolabs, formally launched in 2024, continues this legacy by integrating high-resolution analytics into our comprehensive development services.

For more information on our full suite of analytical capabilities, please see our parent hub page.
Vector | CMC | Analytics Services

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities